Skip to main
WVE
WVE logo

WVE Stock Forecast & Price Target

WVE Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

WAVE Life Sciences Ltd demonstrates a positive outlook due to its robust RNA medicines platform, PRISM, which is positioned to transform treatments for both rare and prevalent diseases, leveraging innovative modalities such as RNA editing and antisense silencing. Encouraging data from its clinical programs, particularly regarding the INHBE/ALK7 pathway for obesity treatment, supports the potential for infrequent dosing regimens that could enhance patient adherence and effectiveness. Furthermore, preliminary results indicating co-treatment with tirzepatide leading to improved body weight reduction underscore the differentiated capabilities of WAVE's RNA editing technology, bolstering confidence in its potential for market success.

Bears say

WAVE Life Sciences Ltd faces significant risks that could adversely impact its stock performance, including potential failures in clinical studies for key programs WVE-004 and WVE-N531, which may also struggle to secure regulatory approval. Furthermore, if these programs fail to meet peak commercial revenue estimates due to limitations in market size, penetration, or pricing, the financial outlook for the company could worsen. Recent data suggests limited therapeutic progress, with insufficient recruitment of anti-inflammatory macrophages and unclear effects on key obesity-related biomarkers, raising concerns about the efficacy of their RNA-targeting modalities.

WVE has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Wave Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Wave Life Sciences (WVE) Forecast

Analysts have given WVE a Buy based on their latest research and market trends.

According to 12 analysts, WVE has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Wave Life Sciences (WVE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.